← Back to Clinical Trials
Recruiting NCT07096999
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Trial Parameters
Condition Metastatic Castration-Resistant Prostate Carcinoma
Sponsor University of Michigan Rogel Cancer Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex MALE
Min Age 18 Years
Max Age N/A
Start Date 2025-01-23
Completion 2031-01-23
Interventions
Non-Interventional Study
Brief Summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Eligibility Criteria
Inclusion Criteria: * \* 177Lu-617 PSMA treatment scheduled for mCRPC * Clinically stable as determined by the nuclear medicine clinicians * Male * ≥ 18 years of age * Willing and able to provide informed consent Exclusion Criteria: * Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed